Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a global medical technology company focused on surgical solutions for spinal, orthopedic, and wound care disorders, with a portfolio centered on orthobiologics and spinal implant systems. The XTNT news feed on Stock Titan aggregates company-issued updates and regulatory disclosures so readers can follow how Xtant communicates its strategy, product launches, and financial performance.
Recent news releases describe Xtant’s emphasis on its core biologics business and regenerative medicine capabilities. The company has announced the commercial launch of products such as CollagenX™, a bovine collagen particulate product for surgical wound closure, and OsteoFactor Pro™, a growth factor-based biologic designed to improve bone healing across orthopedic and spine procedures. Xtant has also introduced Trivium™, a next-generation demineralized bone matrix allograft, and nanOss Strata™, a synthetic bone graft manufactured from hydroxycarbonapatite and designed to mimic human bone structure and support osteoconductivity and cellular activity.
Company news also covers strategic transactions and portfolio changes. Xtant has reported entering into, and subsequently completing, the sale of certain non-core Coflex and CoFix spinal implant assets and its Paradigm Spine GmbH international hardware business to Companion Spine entities, describing these divestitures as a way to sharpen its focus on biologics and strengthen its balance sheet.
Investors and analysts following XTNT news will find quarterly earnings announcements, including revenue trends, gross margin, net income, adjusted EBITDA, and cash flow metrics, as well as financial guidance for the year. The company also issues notices about participation in investor conferences, annual meeting details, and governance developments such as changes to its Board of Directors and amendments to equity incentive plans.
By reviewing the XTNT news stream, readers can see how Xtant presents its mission of honoring the gift of donation, its product development priorities in orthobiologics and wound closure, and the financial and strategic milestones it reports through press releases and SEC-related communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Xtant Medical Holdings (NYSE American: XTNT) will announce its Q1 2023 financial results on May 4, 2023, before market open. A conference call will follow at 9:00 AM ET, led by CEO Sean Browne and CFO Scott Neils, to discuss the results. Interested parties can join through dial-in numbers or via a webcast registration link provided in the release. Xtant Medical specializes in medical technology, focusing on orthobiologics and spinal implant systems for spinal fusion procedures. The company emphasizes integrity and dedication in serving its customers. For further information, a replay of the call will be accessible on the company's website after the live event.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported strong fourth quarter and full year 2022 financial results, with revenues growing 9% to $15.3 million for Q4 and 5% to $58.0 million for the full year. The company's biologics products drove a 14% revenue increase in Q4. Despite a decline in gross margin to 54.4% due to higher production costs, the acquisition of the Coflex® product line enhances its offerings. The net loss for 2022 increased to $8.5 million, or $0.09 per share, signaling challenges despite revenue growth. A conference call is scheduled to discuss these results further.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is set to release its financial results for the fourth quarter and full year ended December 31, 2022, before the market opens on March 7, 2023. The results will be discussed in a conference call hosted by CEO Sean Browne and CFO Scott Neils at 9:00 AM ET on the same day. Investors can participate by calling 877-407-6184 or registering for the webcast on the company’s website. Xtant specializes in surgical solutions for spinal disorders, focusing on orthobiologics and spinal implant systems designed to facilitate spinal fusion.